These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36089643)

  • 41. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase separation underlies signaling activation of oncogenic NTRK fusions.
    Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
    Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
    [No Abstract]   [Full Text] [Related]  

  • 44. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tropomyosin receptor kinases in sarcomas - of joy and despair.
    Dieckmann N; Schildhaus HU; Bauer S
    Curr Opin Oncol; 2021 Jul; 33(4):336-344. PubMed ID: 33989242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Haratake N; Seto T
    Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Novel targeted therapeutic option in oncology: tropomyosin receptor tyrosine kinase inhibitors].
    Kiss E; Pápai Z
    Orv Hetil; 2021 Aug; 162(34):1362-1369. PubMed ID: 34428172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
    Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB
    Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
    Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
    Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
    Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
    Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How selecting best therapy for metastatic
    Ekman S
    Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas.
    Demols A; Rocq L; Perez-Casanova L; Charry M; De Nève N; Ramadhan A; Van Campenhout C; De Clercq S; Maris C; Closset J; Lucidi V; Salmon I; D'Haene N
    Oncologist; 2023 Jul; 28(7):e520-e525. PubMed ID: 36994874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
    Orbach D; Sparber-Sauer M; Laetsch TW; Minard-Colin V; Bielack SS; Casanova M; Corradini N; Koscielniak E; Scheer M; Hettmer S; Bisogno G; Hawkins DS; Ferrari A
    Eur J Cancer; 2020 Sep; 137():183-192. PubMed ID: 32784118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.